Zoonotic-origin infectious diseases are one of the major concerns of human and veterinary health systems. Ticks, as vectors of several zoonotic diseases, are ranked second only to mosquitoes as vectors. Many ticks’ transmitted infections are still endemic in the Americas, Europe, and Africa and represent approximately 17% of their infectious diseases population. Although our scientific capacity to identify and diagnose diseases is increasing, it remains a challenge in the case of tick-borne conditions. For example, in 2017, 160 cases of the Brazilian Spotted Fever (BSF, a tick-borne illness) were confirmed, alarming the notifiable diseases information system. Conversely, Brazilian borreliosis and ehrlichiosis do not require notification. Still, an increasing number of cases in humans and dogs have been reported in southeast and northeastern Brazil. Immunological methods applied to human and dog tick-borne diseases (TBD) show low sensitivity and specificity, cross-reactions, and false IgM positivity. Thus, the diagnosis and management of TBD are hampered by the personal tools and indirect markers used. Therefore, specific and rapid methods urgently need to be developed to diagnose the various types of tick-borne bacterial diseases. This review presents a brief historical perspective on the evolution of serological assays and recent advances in diagnostic tests for TBD (ehrlichiosis, BSF, and borreliosis) in humans and dogs, mainly applied in Brazil. Additionally, this review covers the emerging technologies available in diagnosing TBD, including biosensors, and discusses their potential for future use as gold standards in diagnosing these diseases.
Introduction:Brazilian spotted fever caused by Rickettsia rickettsii is the most important rickettsiosis and the only reportable tick-borne disease in Brazil. Its diagnosis is often treated based on clinical diagnosis and/or indirect immunofluorescence. Objective:The aim of this study was to using high affinity epitope peptide from the OMP H6PGA4_ RICRI, previously identified by our group, to develop a cyclic voltammetry-peptide based immunosensor for the diagnosis of the human disease. Methodology:The construction of an immunosensor from the use of ultra-specific epitopes identified by peptide microarray receiving elements used as capture antibody, was developed successfully. The electrochemical technique of cyclic voltammetry was performed on the detection signal generated by interaction between the peptide and the antibody circulating in blood samples. Printed electrodes of carbon and glutaraldehyde solution were used for fixing the electrode epitopes. Amperometric responses were generated by applying a potential of -0.6 to 0.6 V, speed of 0.025 V/s, using 20 cycles of scans. Results:A detection limit of10 ng mL-1 and sensitivity 2.59 μA were obtained, allowing proper clinical diagnosis. The performance of the assay was evaluated using human serum samples from infected and healthy patients. The accuracy was demonstrated by the analysis of 20 cycles of scanning and the performance against sera of healthy individuals.The peptide-immunosensor chip was reproducible with a coefficient of variation ≤10,1%.The sensitivity of serum dilution was 1: 100. Conclusion:The IgG biosensor-peptide test has high sensitivity, and, because it is quick and easy to perform, would be good screening test for acute spotted fever infection. IgG peptidebiosensor has good specificity, and is comparable with the ELISA -peptide and is able to identify in real time circulating antibodies. The construction of this immunosensor, able to identify in real time specific antibodies can be applied in the diagnosis of other infectious and parasitic diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.